The spate of recent deals involving antibody-drug conjugates (ADC) continues in a field composed of record-breaking agreements in 2023. The newest of the deals were focused on Asia. GSK plc entered a license deal for the exclusive rights for clinical development and commercialization of Hansoh Pharmaceutical Co. Ltd.’s B7-H3-targeted ADC, HS-20093. Also, South Korea’s Dong-A ST Co. Ltd. is expanding into the ADC space by acquiring Abtis Co. Ltd. and its Abclick platform for ADC drug development.
Gemigliptin Market is Likely to Reach US$ 2 59 Billion by 2030, expanding at Over 5 4% CAGR: Coherent Market Insights | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
BOSTON, Aug. 14, 2023 /PRNewswire/ NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of. -Today at 08:02 am- MarketScreener
/PRNewswire/ DelveInsight s Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia areata.